Delving into the Latest Updates on HML-109 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

Oxygain, HML-109, HRC-101

Target

Hemoglobins

Action

modulators

Mechanism

Hemoglobins modulators

Therapeutic Areas

Immune System DiseasesHemic and Lymphatic Diseases

Active Indication-

Inactive Indication

Transfusion Reaction

Originator Organization

1608557 Ontario, Inc.

Active Organization-

Inactive Organization

1608557 Ontario, Inc.

License Organization-

Drug Highest PhaseDiscontinuedDiscovery

First Approval Date-

Regulation-

Anesthetized rats were hemodiluted (180 ml kg(-1)) with low (P(50) approximately 70 mmHg) or high affinity (P(50) approximately 14 mmHg) HRC 101 at hemoglobin (Hb) concentrations near 100 or 70 g l(-1) (n = 6-8). Hippocampal tissue oxygen tension (P(Br)O(2)), blood flow, arterial blood gases, Hb, hematocrit (Hct) and lactate were measured. Data (mean +/- SD) were analyzed by two-way ANOVA.

RESULTS:

Hemodilution reduced the hematocrit to 1 +/- 1% in all groups. P(Br)O(2) was best maintained after hemodilution with low affinity HRC 101 at Hb 100 and 70 g l(-1) (25.2 +/- 7.6 and 16.6 +/- 8.3 torr, respectively). P(Br)O(2) decreased (9.5 +/- 9.3 torr, P < 0.05) and serum lactate levels increased (5.0 +/- 1.7 mmol l(-1), P < 0.05) following hemodilution with the high affinity HRC 101 (Hb 100 g l(-1)).

CONCLUSIONS:

HRC 101 with a lower oxygen affinity favored tissue perfusion and maintained P(Br)O(2) after near complete blood volume exchange in rats.

100 Deals associated with HML-109

Login to view more data